Recent improvement in survival is primarily due to the advances in therapeutics, that is, cystic fibrosis transmembrane conductance regulator (CFTR) modulators, or CFTR corrector and potentiator medications, which ameliorate pulmonary disease [8]. This evidence concerns the gene CFTR and lung disorder.